Howe & Rusling’s BioCryst Pharmaceuticals BCRX Stock Holding History

Howe & Rusling’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-100	Closed	-$1K	–	1058
2022 Q2	$1K	Buy	+100	New	+$1.03K	﹤0.01%	926

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Howe & Rusling's BCRX Position: Q3 2022 in Review

Howe & Rusling sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 100 shares — an estimated $1K sold.

Howe & Rusling first reported a position in BCRX in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

Howe & Rusling reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Howe & Rusling sold 100 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $1K.
Howe & Rusling first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Howe & Rusling's BioCryst Pharmaceuticals position peaked at $1K in Q2 2022.
234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.